Short report: Surveillance for adverse drug reactions to combination antimalarial therapy with sulfadoxine-pyrimethamine plus artesunate in Peru

Javier Cairo, Salomón Durand, Wilmer Marquiño, César Cabezas, Arnaldo Lachira, Fernando Quintana, Walter Vegas, Trenton K. Ruebush, Gregory Utz, David J. Bacon

Research output: Contribution to journalArticle

4 Scopus citations

Abstract

In 2001, Peru changed its treatment policy for uncomplicated Plasmodium falciparum malaria on the northern Pacific Coast to sulfadoxine-pyrimethamine with atresunate (SP-AS). Because Peru was the first country in the Americas to adopt this combination therapy, we established a surveillance system in the region to assess the frequency of new or worsening symptoms after starting therapy. Over a period of two years, 1,552, or approximately two-thirds of all patients with uncomplicated P. falciparum malaria who had received SP-AS on the northern coast were followed up. Of these, 8.8% reported at least one adverse effect, with the most common being vomiting, nausea, headache, abdominal pain, dizziness, and fever; no severe adverse effects related to SP-AS therapy were identified. Treatment of uncomplicated malaria with SP-AS was associated with a low frequency of mild adverse effects in Peru, and therefore should be considered as a first-line therapy in areas of the Americas where SP efficacy is still high. Copyright © 2008 by The American Society of Tropical Medicine and Hygiene.
Original languageAmerican English
Pages (from-to)42-44
Number of pages3
JournalAmerican Journal of Tropical Medicine and Hygiene
StatePublished - 1 Jul 2008
Externally publishedYes

Fingerprint Dive into the research topics of 'Short report: Surveillance for adverse drug reactions to combination antimalarial therapy with sulfadoxine-pyrimethamine plus artesunate in Peru'. Together they form a unique fingerprint.

  • Cite this